Therapeutic Application of Microsponges-Based Drug Delivery System

Mahfoozur Rahman¹, Waleed HAlmalki², Sunil K Panda³, Aman Kumar Das¹, Saad Alghamdi⁴, Kirti Soni⁵, Abdul Hafeez⁶, Mayank Handa⁷, Sarwar Beg⁸*, Ziyaur Rahman⁹*

¹Department of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Technology &Sciences, Allahabad, India

²Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Saudi Arabia

³Menovo Pharmaceuticals Research Lab, Ningbo, People's Republic of China

⁴Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia

⁵Formulation Development, Dabur Research Foundation, 22 Site IV Sahibabad Industrial Area, Ghaziabad, Uttar Pradesh, India

⁶Glocal School of Pharmacy, Glocal University, Mirzapur Pole, Saharanpur, Uttar Pradesh, India

⁷Department of Pharmacuetics, NIPER, Raebareli, Lucknow, Uttar Pradesh, 226002

⁸School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK

⁹Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX 77843
*Address for correspondence:*
Dr. Sarwar Beg, School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK, Email: sarwar.beg@gmail.com

Dr. Ziyaur Rahman, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX 77843, Email: rahman.ziyaur@gmail.com
Abstract

Microsponges delivery systems (MDS) are highly porous, cross-linked polymeric systems that activate in the presence of temperature, rubbing, and pH. MDS offer a wide range of advantages, like controlled drug release, site-specific action, stability over a broad range of pH, less irritation, cost-effectiveness, and improved patient compliance. They can be transformed into various dosage forms like creams, gels, and lotions. MDS-based systems are suitable for the treatment of topical disorders like acne, psoriasis, dandruff, eczema, scleroderma, hair loss, skin cancer, and other dreadful diseases. MDS application for drug delivery is not limited to topical drug delivery but is also explored for oral, parenteral, and pulmonary drug delivery. Microsponges were studied for colon targeting of drugs and genes. Additionally, MDS have several applications such as sunscreen, cosmetics, and over-the-counter (OTC) products. Furthermore, MDS do not actuate any irritation, genotoxicity, immunogenicity, or cytotoxicity. Therefore, this review extensively highlights microsponges, their advantages, key factors affecting their characteristics, their therapeutic applications in topical disorders and in cancer, their use as cosmetics, as well as recent advances in MDS and the associated challenges.

Keywords: Microsponges; Nanosponges; Oral delivery; Topical applications; Skin irritation; intestinal membrane.
1. Introduction

Oral-based conventional dosage forms release the drug in the gastrointestinal (GIT) fluid which causes variation in absorption of the drugs throughout the intestinal membrane. A wide range of conventional formulations are administered orally for immediate drug release activity. However, oral route of drug administration suffers from incomplete drug absorption and rapidly cleared from the body leading to compromised therapeutic performance. The conventional topical dosage forms allow permeation of active pharmaceutical ingredients (API) through the skin to the underlying skin layers [1,2]. The release of drug from the conventional topical dosage forms into epidermis remains fundamentally restricted due to skin barriers which also provides short duration of therapeutic action [1,3,4]. Furthermore, topical route encounters with limitations like aesthetically unappealing, unpleasant smell, oiliness, stickiness, and may causes irritation, allergic reactions and suboptimal response in the patient. Additionally, these carriers needed in higher concentrations to deliver an active ingredients for better therapeutic action [5]. Novel drug delivery systems surpass these limitations associated with conventional topical and oral delivery systems. These advancements in the field of delivery systems imparts enhancement in the efficacy and reduced cost of the treatment [6]. Therefore, emergence of microsponges-based delivery systems can uniquely solve the problems associated with the conventional topical and oral dosage forms.

Microsponges delivery systems (MDS) are porous, highly cross-linked, polymeric systems constituted from the porous microspheres. MDS captures various drugs and provides tailored release profile when administered via skin/GIT. These carriers its activation under temperature and pH [7]. The microsponges can be transformed into dosage forms like creams, gels and lotions for the treatment of various topical disorders like acne, psoriasis, dandruff, eczema, scleroderma, hair loss, skin cancer, and other dreadful diseases [4,8]. MDS has a wide range of advantages like controlled drug release, site-specific action, stability over a wide range of pH, cost effective manufacturing, poor irritation and improved patient compliance. Microsponges have good ability for drug adsorption or absorption. They can encapsulate more than 3-fold of their weight, and makes an alluring carrier from other types of delivery systems [2,9–12]. In addition, it limits the irritation of effective medications without compromised efficacy. Further, controlled drug release into the skin can be accomplished through diffusion mechanism and
provides advantages like enhanced product efficacy, tolerability, mildness, and reduced irritation [13]. MDS is not limited to topical drug delivery, but it is broadly studied for oral, parenteral, and pulmonary drug delivery applications. This review, therefore, extensively highlights about microsponges, and their advantages, key factors affecting the microsponges characteristics, therapeutic application of microsponges in topical disorders and cosmetic preparation, along with recent advances in MDS preparation, characterization, stability and toxicity evaluation.

2. Microsponges compositions

On the basis of dermal toxicity studies, various polymers have been explored so far. The modelling of microsponges consists of Eudragit® or polymethacrylates polymers (Eudragit RSPO, Eudragit RS100, Eudragit S100), polylactic acid, polylactide-co-glycolic acid, polyhydroxy butyrate, polydivinyl benzene, ethyl cellulose. From above mentioned polymers, Eudragit RS100 is the primarily used and widely studied polymer because of its universal nature and biocompatibility. Eudragit-based polymers differ in characters like water permeability, and solubility which accounts for designing pre-determined drug release profiles in MDS system. Thus, it facilitates numerous alternatives to achieve the desired physicochemical properties [14–16]. Polymethacrylate polymers are non-toxic, safe and budgetary excipients, that widely accepted in pharmaceutical formulation and approved by US Food and Drug Administration (FDA). Different polymethacrylate polymers can be combined and exhibits controlled drug release behaviour[17]. Ethyl cellulose is used as the base material for the preparation of microsponges, as it is non-toxic, non-allergenic and non-irritating in nature [18,19]. Polydivinyl benzene is used for fabrication of porous microspheres with the help liquid-liquid suspension polymerization method[20,21].

Till now, a wide range of polymers used in MDS are explored, but biodegradable polymers are least studied. Biodegradable polymers are promising excipients for microsponges development as carriers for drug delivery and targeting [22]. Additionally, triethyl citrate is employed as plasticizer for stabilization of the microsponges [2,23]. Cellulose ethers and polyvinyl alcohol (PVA) are used as emulsifying agents for maintenance of aqueous phase consistency by using quasi-emulsion solvent diffusion method [24]. Whereas, sodium bicarbonate or hydrogen peroxide forms equitable distribution and interconnection of pores as well as the availability of higher surface area for high drug loading. These interconnected pores, provide high entrapment
efficiency to these micro-colloidal drug delivery systems [25,26]. As per the literature review, pre-gelatinized starch and sucrose are utilized as inducers for pore, that improves the drug release characteristics[27,28].

3. **Characterizations of microsponges**

There are certain factors that affect microsponges characteristics include shape, particle size, encapsulation efficiency, porosity, surface morphology, drug loading and drug release.

3.1. *Particle size and distribution*

The particle size and its distribution are essential parameters in the preparation of microsponges. Various factors that affect size of microsponges include its internal phase volume, polymer-drug ratio, stirring speed, emulsifier concentration, etc. [14]. The particle size range for the topical application is 10-25 µm [29]. The particle size affects drug loading and release profile from microsponges. It is important to characterize the particle size and its distribution as it greatly affects the texture and stability of the formulation. Increasing drug-polymer ratio produces small particles, while increase in the amount of emulsifier results in large-sized microsponges.

3.2. *Surface topography and morphology*

Different methods like scanning electron microscopy (SEM), photon correlation spectroscopy (PCS), transmission electron microscopy (TEM) have been employed to understand the morphology and surface topography of microsponges [30]. Various researchers have reported the microsponges morphology and demonstrated presence of pores on the carriers’ surface. Temperature and solvent in inner phase affects the microsponges morphology during the process of formulation. Another parameter, related to the solvent system is about the production of snappy polymer precipitation that results in less or non-porous surface [31,32].

3.3. *Pore structure, Production yield and Loading efficiency*

Pore diameter and volume are crucial in regulation of drug release. The production yield parameters are affected by polymer-drug ratio, amount and type of emulsifier used, and mixing speed. Jain and Singh formulated dicyclomine microsponges that have exceptionally less yield with polymer-drug ratio of 1:1, while at polymer-drug ratio of 5:1, results in higher production yield. Drug loading in microsponges is carried out by two methods such as passive loading
(single-step process) and active loading (double-step process). Passive loading is simple, advantageous and more effective than active loading. The drug loading efficiency can be enhanced by enhanced drug-polymer ratio and decreases the particle size[33].

3.4. Compatibility Studies

Fourier transform infrared spectroscopy (FT-IR) and thin layer chromatography (TLC) are used to investigate the drug compatibility with reaction adjuncts. Differential scanning calorimetry (DSC) and Powder X-ray diffraction (XRD) are used for the assessment of any polymerization effect on drug crystallinity [11,34].

4. Microsponges: Preparation methods

The method for the preparation of micro sponges was described by Kawashima et al., in 1998 [35]. Usually, microsponges preparation is done by two techniques such as quasi-emulsion solvent diffusion and liquid-liquid suspension polymerization method as shown in Figure 1 and Figure 2[5].

4.1. Quasi-emulsion solvent diffusion (QESD)

QESD is a two-step process for the preparation of microsponges[36]. The internal phase of the polymer-drug solution is prepared in organic volatile solvent such as acetone or ethanol under ultrasonication at 35°C temperature, and plasticizers like triethyl citrate (TEC) are added. The plasticizer is incorporated to promote the plastic properties of microsponges. This is followed by the addition of internal to the external phase under continuous aqueous polyvinyl alcohol (PVA) blending for 2-3 h [37]. Due to vigorous stirring, formulation of quasi-emulsion globules takes place, which allows microsponges separation from mixture by filtration. Washing of microsponges and drying is performed at 40°C for 10-12 h [37]. The key advantage of QESD formulated microsponges includes minimal exposure of the drug to external environment, with miniscule amounts of solvent residues.

4.2. Liquid-liquid suspension polymerization

Microsponges preparation can be done by liquid-liquid suspension polymerization method. The microsponges can be prepared by using methyl methacrylate and ethylene glycol dimethacrylate or styrene and divinylbenzene as the starting materials. The polymerization of styrene or methyl
methacrylate is done in a round bottom flask. In this method, a solution is prepared that consists of water immiscible monomers and API.

With the help of agitation this phase is allowed to suspend in an aqueous phase, ordinarily comprising additives, like dispersants and surfactants, to enhance the suspension formation. When the suspension in the desirable size is obtained, the polymerization process is initiated by enacting the monomers either due to catalysis or irradiation or elevated temperature. As if the polymerization process proceeds, the spherical structures are obtained with incorporation of thousands of microsponges grouped together like grapes, and shape of interconnecting reservoirs. After completion of the polymerization process, the solid particles obtained are recoupled from suspension. After that processing with solid particles is done until they are considerably prepared for use [38,39].

5. Microsponges: Drug release mechanistic insights

Microsponges consist of porous microspheres with an entangled channel of interconnecting voids and a non-collapsible structure. For the topical application of formulation to the target area on the skin, API must diffuse out of porous microspheres into the vehicle. Also, API release rate from the formulation can be pre-fixed to achieve a customized drug release profile. In oral applications, the microsponge system has been shown to increase the rate of solubilisation of poorly water soluble drugs by entrapping such drugs in the pores of the microsponges. As these pores are very small, the drug is in effect reduced to microscopic particles and the significant increase in the surface area thus greatly increases the rate of solubilisation.

The release can be governed by one or more triggers like changes in the pH, pressure, temperature, solubility, etc. [7,12,40,41].

- **Pressure:** Active ingredients gets released from microsponges to the skin due to continuous rubbing or application of optimal pressure [10,42].
- **Solubility:** Microsponges containing soluble/less soluble API are released to the skin through a diffusion process and majorly relies on ingredient partition coefficient between the microsponges and external skin surface.
- **pH:** The change in pH triggers API release from the microsponge formulation. This can be done by adjustment to microsponges covering.
Temperature change: Alteration in temperature regulates drug release from the microsponges. At certain room temperature, some API continuously diffused from microsponges into the skin. This can be troublesome and to counterfeit this issue, modification in the skin temperature helps in controlling the drug diffusion rate and the overall drug release profile. In topical semisolid formulations, the drug release can be investigated with the help of Franzstatic diffusion cells [42].

6. Therapeutic Application of Microsponges

6.1. Topical applications

Microsponges are used for topical delivery for cosmetic and dermatological applications varies only in their technological parameters (as shown in Table 1). This might be due to the market demand, industrial scalability, regulatory constraints, and short introduction time for dermatological products. Because of high absorbent nature of porous microsponges, various microsponge loaded antiperspirants, deodorants as well as sunscreens are currently available in the market. Localized and site-specific action of MDS prevents unnecessary retention of the drug into the percutaneous blood circulation and found to be effective for topical disorders such as like acne, psoriasis, skin cancer, wounds, wrinkles, hyperhidrosis, sunburn, and alopecia, etc. [41]. Bhatia and Saini formulated curcumin microsponges by QESD technique using polyvinyl alcohol (PVA) and ethyl cellulose as carriers. Ex vivo drug deposition studies of microsponges loaded in carbopol gel demonstrates 77.5% curcumin permeation within 24 h. Thus, curcumin loaded microsponges can be a promising alternative for topical delivery systems with advantages like curcumin delivery in a continued way to decrease the recurrence of administration and enhances its bioavailability [43]. Acetazolamide is a carbonic anhydrase inhibitor useful for the treatment of glaucoma from a long time. Higher oral doses of acetazolamide are used to bring down the intraocular pressure. This usually has several side effects and decreased patient compliance results in discontinuation of the therapy. To overcome this problem of oral acetazolamide, Obiedallah et al prepared acetazolamide microsponges. In situ gel was formulated with an aim for ocular drug delivery and enhanced therapeutics efficacy and lowers the systemic side-effects. The prepared in-situ gel was further assessed for physical and chemical properties (like pH, rheological properties, and gelling time) along with in-vivo investigations. The formulation with polymer-drug ratio 1:2 demonstrated shigher entrapment efficiency of
~82%, average particle size of 10 µm, that are appropriate characteristics for ocular delivery. Furthermore, it is non-irritant to rabbits’ eye and improved therapeutic efficacy in contrast with the free drug in gel. Thus, acetazolamide-loaded microsponges in situ gel formulations can be a superior option in contrast to oral acetazolamide for glaucoma treatment [44]. Some prominent examples of microsponges based cosmetic products commercially available are enlisted in Table 2.

6.2. Microsponges for anti-acne drugs

Chronic inflammatory disorders like acne, are related to pilosebaceous unit (PSU) and described by different variations in immunological host responses, sebum productions, bacterial proliferation, follicular epithelial desquamation, inflammation [45]. Acne occurs for the most part on the face, chest and back [46]. Acne normally starts during pubescence and is outlined by puberty. It usually happens in females and males, which are aged between 14-17 and 16-19 years, respectively. Acne pathogenesis is controlled by hypersecretion of sebum in distorted follicles, that results in follicular hyperproliferation and microcomedones that ultimately leads to inflammation, and comes out with pustules, papules, cysts, and nodules. The main causative agent of acne is Propionibacterium acne (P. acne) [47]. For moderate and mild acne topical treatment is the best option while for moderate and severe acne systemic treatment is beneficial. Acne treatment usually normalizes the keratinization process, reduces the interfollicular P. acne, and significant reduction of inflammation and sebaceous gland activity. Localized topical acne treatment comprises of moieties, primarily or first line keratolytic agents (retinoids and its derivatives, benzoyl peroxide, azelaic acid, salicylic acid) along with antibiotics (erythromycin and its zinc complexes, clindamycin). These are ordinarily utilized topical agents. However, these agents are associated with side-effects such as skin dryness, irritation and peeling or bacterial resistance. Such issues limit compliance of patient and compromised therapy. To defeat such issues and to minimize the dose of anti-acne agents, demands the proposal for novel drug delivery systems [45]. Roughly novel carriers with potential, vesicular and particulate drug delivery systems such as microemulsions, liposomes, microspheres, solid lipid nanoparticles, nano-lipid carriers’ investigation has been underway for improved anti-acne topical therapy [45]. Benzoyl peroxide (BPO), which is utilized as a topical first line anti-acne agent, has prominent bactericidal activity towards P. acne[48]. BPO moiety is superior to all antibiotics due to failure
of bacterial protection from it. In any case, significant disadvantage related to BPO treatment includes skin irritation effect. Jelvehgari et al., formulated microsponges for facilitation of BPO delivery. QESD method was selected for ethyl-cellulose-based microsponges preparation. BPO-loaded microsponges were loaded into creams and investigated for drug release. The morphology of the microsponges was studied using SEM. The micrograph depicted porous spherical microspheres. Dispersed phase volume, polymer-drug ratio, stirring rate affects the microsponges particles size and drug release pattern. These studies predicted an enhancement in the drug-to-polymer ratio and reduce BPO release from microsponges. This may be ascribed to decrement in porosity. The controlled release of BPO to skin can change the dose relationship between skin irritation and efficacy [49]. Another drug of choice is erythromycin for acne treatment because of its bacteriostatic action against P. acnes [50]. In any case, the drug induces nausea, vomiting, gastric irritation, pain in the abdomen and is easily metabolized at gastric pH. Ravi and coworkers formulated erythromycin loaded microsponges loaded gel which exhibited lesser skin bothering, slow drug release, and high skin tolerance. Osmani et al., prepared microsponges-loaded miconazole nitrate topical cream as an empowering localized formulation for acne and topical infections[9,51].

6.3.Microsponges for anti-psoriasis drugs

Psoriasis is another chronic inflammatory skin disorder that affects roughly 2% of the total population. It is interceded by the cells and molecules of innate and adaptive immune systems. Psoriasis includes chronic plaque psoriasis, pustular psoriasis, nail psoriasis, guttate psoriasis, erythrodermic psoriasis [52,53]. It is described by extraordinarily expanded proliferation along with incomplete epidermal differentiation, and significant increment in cutaneous blood flow, and leukocytic penetration into epidermis and papillary dermis [54]. The majority of patients initially prescribed with topical therapy (Dithranol and tar, Vitamin D₃ analogues, topical corticosteroids, Retinoids, calcineurin inhibitors, etc.) followed by phototherapy and systemic treatment with biological agents such as cyclosporine, infliximab, ixekizumab, secukinumab, guselkumab, etc. Limitations with topical agents include skin staining, calcium metabolism, teratogenicity etc. and biologicals (high relapse rate) with confined application[55]. Clobetasol propionate (CP) belongs to class of super potent dihalogenated topical corticosteroid used against psoriasis due to its vasoconstrictive, anti-inflammatory, antiproliferative activities. It has regular
side-effects such as steroid acne, skin atrophy, allergic contact dermatitis, hypopigmentation and systemic penetration on topical usage. The use of novel topical carrier and delivery systems address the side effects related to CP and give a prolonged term of action via controlled drug release. Neelam et al. utilized microsponges to facilitate the delivery of CP. They used quasi-emulsion solvent diffusion method to develop CP loaded micro sponges. Further, CP loaded microsponges were formulated into carbopol gel base. Polymer to drug ratio, aqueous and organic phase volume, stirring rate, surfactants were likewise considered. Enhancement of drug to polymer ratio results in enhanced entrapment efficiency of microsponges. Microsponges as a delivery system brought about extended release of CP and improved therapeutic action, with least toxic effects [56]. Microsponges for psoriasis are summarized in Table 2.

6.4. Microsponges for atopic dermatitis

Atopic dermatitis (AD) is a typical chronic skin disease portrayed by relapsed eczema with pruritis as an essential sore [57,58]. It happens in around 17-24% paediatric population and in 4-7% of adults [59]. It is a multifocal skin disease with numerous etiologies. The treatment level of AD is based on its severity. Present treatments of AD is focused on the reclamation of skin’s barrier function, principally through moisturizers and therapeutics include corticosteroids for inflammation, immunosuppressive drugs, topical calcineurin inhibitors in chronic cases. Newer biological agents like interleukin (IL)-4/IL-13 antibodies, micro and nanotechnologies are also available [60]. An antihistaminic drug hydroxyzine hydrochloride is also used for the treatment of atopic dermatitis and urticaria. Oral administration of this drug causes most common side effects like dizziness, blurred vision and anticholinergic responses. Microsponges were utilized as nanocarrier, for topical hydroxyzine hydrochloride administration with an aim to lower side effects and targeting to a specific action. Zaki and coworkers tailored the release of hydroxyzine hydrochloride from the formulation could bring downside effects as well as absorption via percutaneous route. Eudragit RS100-based drug-loaded microsponges were prepared by a diffusion method utilizing oil as solvent, acetone as dispersing solvent and liquid paraffin as the continuous phase. Magnesium stearate was added to the dispersed phase for inhibition of flocculation while pore inducers like sucrose along with PGS was utilized to improve the drug release rate. Microsponges with about 60-70% porosity and 98% encapsulation efficiency were obtained. In-vitro study was done on histamine-sensitized rabbits to investigate the
pharmacodynamic effect of prepared microsponges [61]. Fluocinolone acetonide (FA) is an engineered hydrocortisone subsidiary, that is fundamentally used in dermatology to decrease skin inflammation [62]. Fluocinolone acetonide entrapped microporous particles were prepared by D’souza and Harinath[63]. This approach limits the percutaneous absorption by tailored release of drug from the formulation. Mometasone is a synthetic 16-α-methyl derivative of beclomethasone and topical glucocorticoid useful in the management of scalp psoriasis, atopic dermatitis, seborrheic dermatitis, etc.[64,65]. It lowers the side effects and sufficient percutaneous absorption is achieved after topical application. Rekha and coworkers developed mometasone furoate-loaded microsponges by using QESD method[66]. The factors that affect the physical parameters of formulation were determined in order to optimize the formulation. FTIR spectroscopy was done to study the excipient and drug compatibility. Microsponges morphology, loading efficiency and production efficiency were also studied. It was seen that particle size and drug release pattern of microsponges were influenced by the polymer:drug ratio, stirring rate, volume of internal and external phase. Paeonol, is bioactive phenol obtained from plants like Paeonia lactiflora, Paeonia suffruticosa, Arisaema erubescens and Dioscorea japonica[67]. Paeonol ointment is used for treatment of dermatitis [68]. However, it is unable to permeate the stratum corneum because of its poor aqueous solubility and limited partition coefficient. QESD method was employed for the preparation of microsponges-loaded Paeonol. Ex vivo and in vivo drug permeation and release studies demonstrated enhanced permeation rate and enhanced drug residence in skin, respectively. A decrease in the fraction of drug administered to the systemic circulation renders an additional advantage of decreasing the adverse effects linked with the drug[14].

6.5. Microsponges for skin cancer

Skin cancer is the most widely recognized, especially in Caucasian populations (White-skinned), affecting almost one million Americans per year [69–71]. Skin cancer is a broad term used to define any malignant lesion of the skin. Skin cancers can be broadly classified into two types depending upon its nature: melanoma and non-melanoma skin cancer (Nmicrospongesc). Nmicrospongesc can be partitioned into cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) [70–72]. The aetiology of cancers is due to environmental exposures and specifically to solar UVB (ultraviolet-B) [71]. When the UV radiation falls on the skin produces
explicit keratinocytes mutations resulting to NmicrospongesC. BCC for the most part happens on face as well as the back of hands, while SCC occur on both the neck and head. Cutaneous malignant melanoma (CM) is the deadliest form of skin cancer and mostly occurs on the lower legs of women and on the men trunk. Major treatment strategies for skin cancer are radiotherapy and surgery; whereas topical chemotherapy along with fluorouracil (FU), retinoids, diclofenac sodium, imiquimod, oral therapy with retinoids, photodynamic therapy, cisplatin, laser surgeries. A genuine worldwide health trouble is actinic keratosis (AK), that may advance to SCC [73]. 5-Fluorouracil is FDA affirmed for the topical treatment of AK, Bowen’s disease and superficial BCC. 5-FU is a pyrimidine analogue, an anti-neoplastic antimetabolite blocks the enzyme liable for the synthesis of thymidine (DNA), alters the DNA replication and subsequent induction of apoptosis [69,72]. 5-FU topical cream (5%) is one of the first-line treatment choices. However, its local tolerance and skin permeation are poor and cause inflammation, itching and irritation [74]. FU contained hydrophilic petrolatum or simple base of propylene gel for topical application. The in-vitro drug release has been examined on porcine skin and human skin. Levy et al. used human cadaver skin to compare the in-vitro skin permeation of three microsponges formulations-loaded with 0.5% FU in Efudex cream[75]. The applied dose is about 10 mg/cm², along with mass balance studies were performed. Every one of the three microsponges formulations released more noteworthy amounts of FU in skin (86-92%) in contrast with commercial formulations (54% drug release) [72]. From the study, that include trials on 356 patients affected with actinic keratosis (actinic keratosis may progress to SCC), the 5-FU microsponge based formulation is more efficacious in comparison to respective vehicle when applied for one week. The therapy was successful in all patients during the entire treatment duration [73]. The optimized microsponge formulation has better aesthetic properties, improved stability and ease to prepare with cheaper ingredients and can be substitute for conventional counterpart for skin cancer treatment [74].

6.6. Microsponges for cosmetics

Cosmetics intended for use can be defined as “articles intended to be poured, rubbed, sprayed sprinkled on, introduced into, or otherwise applied to the human body for altering the appearance, beautifying, cleansing, and promoting attractiveness” [76]. Cosmetics in the present time should be free of perfumes, mineral, oils and lanoline; so that they will be safe, last long,
cheaper and act as moisturizers [77,78]. Microsponge system is excellent for skin, cosmetics and care products. They are capable of retaining several times their weights in liquids, react to different triggers and absorb the excessive skin oil. This provides an exquisite feeling on the surface of the skin. Various cosmetic and toiletry companies are currently using this technology to prepare several cosmetic and OTC products. These microsponge-based products have superiority over conventional formulations in terms of enhanced chemical and physical stability, tailored release of API, higher release rates, less skin irritation and unique palpable characteristics [79]. The microsponges delivery system allows the preparation of formulations containing at least two ensnarement’s that have commonly contrary API like retinol and hydroquinone. Also, aqueous gels contain lipophilic material and prepared without using of any emulsifier. This is possible because the entrapped materials are inside the permeable microsponge particles, and these are handily wetted and suspended in the aqueous phase. On the contrary, highly lipophilic products can be prepared using entrapped hydrophilic materials, again without the use of emulsifiers or surfactants because the microsponge particles are handily wetted and suspended in the lipid stage because of the amphiphilic nature of the polymer used in microsponges fabrication [80].

6.6.1. Cosmeceuticals

Cosmeceuticals are one of the rapidly growing fields in the skin care business. Some of the examples of cosmeceutical substances are like retinol, alpha-hydroxy acids (AHAs), vitamin-K, etc. These ingredients provide several benefits but are accompanied with some side effects like peeling, drying, erythema, etc. Thus, cosmeceutical ingredients entrapped in microsponge polymers can be a better alternative. Retinol, an exceptionally unadulterated type of vitamin A has a great capacity to manage aging and youthful skin appearance [81]. It is highly reactive and gets unstable when blended with different ingredients. A microsponge-based retinol formulation, is cosmetically elegant, stabilized and low skin irritation has been successfully produced and commercially available [79]. Retinol was entrapped in an aesthetically pleasing moisturizing base. These products have shelf-life of 2-3 years and can hold 90% of their initial concentration. Retinol entrapped formulations mixed with other cosmeceutical agents like vitamin K (phytonadione) that is likewise in the captured structure and lessens the presence of dark circles
under the eyes. These entrapped active ingredients make the formulations milder and, thus, appropriate for routine application [80].

6.6.2. Starch microsponges-based topical sunscreen product

Topical sunscreen products are utilized as UV channels engrossing UVA as well as UVB radiations, that shields from destructive solar radiations. Yet, majority of the sunscreen show allergic effects as well as safety issues because of diffusion from the skin into the systemic circulation. Oxybenzone/Benzophenone-3 (BNZ) is USFDA endorsed sunscreen, but topical retention is a major challenge because of its higher penetrability. Various investigations have shown that repeated usage of BNZ containing products, leads to accumulations of higher percentages of BNZ in breast milk and urine. This ultimately leads to melanoma, contact eczema, breast cancer. So, Bhuptani et al. prepared starch microsponges-based sunscreen formulation encapsulated in benzophenone-3 organic sunscreen and characterized by SEM, DSC, nitrogen adsorption/desorption analysis and powder X-ray diffraction. The outcome indicates that starch microsponges had a high surface area for BET (85.45 m²/g) and porous spherical morphology in the size < 200 nm. The optimized formulation was prepared, characterized and clinically tested. Starch microsponges-based sunscreen product possessed good spreading properties, non-sticky, rich texture, and good patient compliance[82]. In vitro and Ex-vivo studies showed that starch microsponges offer higher SPF, enhanced photoprotection, and lowered the cutaneous penetration contrasted with commercial cream (as shown in Figure 3). After preclinical studies, clinical studies confirmed that the prepared starch micro-sponge loaded sunscreen cream was safe to skin and biocompatible (as shown in Figure 4).

6.7. Microsponges for Peroral Drug Delivery

Microsponges have capacity to expand the drug release rate for poorly water-soluble drugs and entrapment of such drugs in their porous microstructure. This enhances the pharmacological effect and bioavailability and decline in the side effects [24,83]. Hence, microsponges-based drug delivery system is appropriate for drug delivery via peroral route. Preliminary studies done by A. P. Pharma, Inc., Redwood City, CA, USA, revealed that microsponges increase oral bioavailability of drugs. It enhances the drug dissolution rate and absorption of drugs. A microsponge system helps in shielding the drug from gastric condition and control the conveyance of drugs to the lower GIT. Microsponges can be formulated into capsules or enteric
tablets as colon-targeting of drugs [24]. The rationale for selecting microsponges as colon-targeted drug delivery because of their particle size is less than 200µm. It becomes easily available for the macrophage’s presence in colon tissue, thus shows a viable confined drug activity at the target site. The compression of 1000-2000 KgF/cm² should be maintained to shape the tablets and prevent the structural deformity of microsponges. The plasticity of Eudragit RS100 takes into consideration the simpler pressure to create a tablet, while plasticity of low plastic polymer can be increased by incorporating a plasticizer like triethyl citrate. Entrapping the core with polymer, solubilizes in acid and externally with enteric polymer helps the formulation remain intact in stomach and begin to dissolve in the small intestine (pH > 6). Consecutively, the dissolution of acid soluble covering relies on the availability of colon bacteria and break up the polysaccharide covering by lowering of pH. In vitro release study was performed using distinctive dissolution media sequentially to simulate GIT conditions and confirmation about enteric coating enteric coating effectiveness against external pH values. For this, artificial intestinal fluid pH 1.2 was used for 2 h, trailed by artificial gastric fluid pH 7.4 for 6 h and simulates the colon fluid with pectinase as long as 16 h. Srivastava and co-workers proposed that tablet, makes drug release to the colon area with transition at 5 h. Jain and coworkers also reported a delay of 6 h until the beginning of release [33]. Orlu et al. fabricated flurbiprofen for colon targeting using pectin-coated tablets with microsponges as core. Their study explained that highly porous spherical microsponges can be obtained by decreasing polymer-drug ratio. They also fabricated tablet for colon-specific targeting with the help of pore plugged method using the same polymeric mixture. Tablet obtained by this method showed zero-order release kinetics. Likewise, Gupta and co-workers explained 5-FU-loaded immediate release in 3 h and commercial product in 4 h. On the other hand, microsponges loaded with HPMC (Hydroxypropyl Methylcellulose) capsule released 97.07% drug in 8 h, indicates reformulation with a requirement for enteric coating[84]. Enteric polymers like Eudragit L100 and Eudragit S100 in various proportions were considered for coating the capsules. Polymers are appropriate for enteric coating and controlled release in the colon[85]. Jain and Singh fabricated dicyclomine-loaded microsponges for colonic release with the QESD method [33]. They observed the particle size of microsponges increases with enhancement in the amount of emulsifier and increase in drug-polymer ratio brought about smaller particles and decreased production yield but elevated amount of drug. The release pattern of the drug from microsponges
best match with Higuchi model. The drug release from floating microsponges (has density lower than gastric fluid) is affected by different pH. Arya *et al.* interpreted curcumin release of 88.4-90.8% toward the finish of 8 h for floating microsponges made of Eudragit RS100 and ethyl cellulose. The loratadine exhibited release of 66.75% and cinnarizine of 57.9% after 8 h from ethyl cellulose microsponges while 97.5% famotidine was released after 12 hours from Eudragit RS100. Higuchi model was found to show better model fitting to describe the drug release from the floating microsponges, which were composed of eudragit, ethyl cellulose, ethyl alcohol and dichloromethane. All the drugs cinnarizine, famotidine, curcumin, and loratadine displayed low water dissolvability. Raghuvanshi and Pathak studied the effect of change in pH on the drug (cinnarizine) release profile. They described that at low pH, the drug exhibited high rate of release [34]. Similarly, Bhatia and Saini also formulated curcumin microsponges by QESD technique using ethyl cellulose and polyvinyl alcohol (PVA) as carriers. They filled the optimized microsponges-loaded in the hard gelatin capsule shell (HGCS) and afterward stacked in carboxer gel to study its ability in peroral and topical delivery system, respectively [43]. Their study results showed that curcumin release was 93.2% by microsponges filled in HGCS and observed only 11.7% curcumin was released from conventional capsule. Also, microsponges based carboxer gel showed 77.5% curcumin release within 24 h. Thus, curcumin microsponges can be a promising alternative for conventional formulation in topical and peroral delivery systems with advantages like controlled and prolonged release of drug. Sulpiride (SUL) is an antidopaminergic drug utilized in the treatment of mental disorders. However, this drug encounters with GIT problems and compromised antiemetic efficacy. Its conventional oral formulation showed an unpredictable and low absorption of the drug with an oral bioavailability of 30%. Younis *et al.* prepared a floating microsponges based gastro-retentive oral formulation of SUL through a QESD method and evaluated their physicochemical aspects. They used Taguchi experimental design and contour plots to streamline some autonomous factors influencing microsponges performance. The encapsulation efficiency, yield, *in vitro* drug release for floatation of optimized SUL microsponges were found to be 79.82 ± 2.37%, 89.11 ± 2.28% and 65% after 8.0 h, respectively. The pharmacokinetics of optimized formulation were performed in rabbits and contrasted with commercial SUL product, Dogmatil® capsules. The optimized SUL microsponges demonstrated a relatively higher $C_{\text{max}}$ (p<0.05), AUC and 2-fold increment via peroral administration in comparison to commercial formulations. Additionally,
the optimized formulation remained available in the stomach for 8 h after administration when imaging was performed through X-ray radiographs in rabbits. Consequently, it may be inferred that floating microsponges can be a better alternative to upgrade the oral bioavailability and pharmacokinetics of Sulpiride[86]. Chlorpheniramine, chemically known as [3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine] is an potent antihistaminic used to mitigate the manifestations of common cold along with allergic responses [87]. Researchers have also investigated coated microsponges as possibility for continued chlorpheniramine maleate release.

Drug-loaded cellulose microsponges were entrapped in Eudragit RS100 to produce powder-coated microsponges. They observed that these systems showed lower $C_{\text{max}}$ and longer $T_{\text{max}}$ in comparison to powder chlorpheniramine maleate, followed by peroral route in dogs. Ibuprofen is a nonselective, nonsteroidal anti-inflammatory drug (NSAID) with good antipyretic activity and effective in management of acute pain associated with acute injuries and migraine headache with moderate and severe intensity [88]. In 2006, Devrim and co-workers fabricated ibuprofen microsponges and investigated the effects of polymers such as Eudragit RS100, Eudragit RL100 and Eudragit RS PM on rheological properties, particle size and drug release profile. They expressed that each and every microsponges had good flow properties, which is essential for controlling dose and uniformity in weight during capsule filling or tablet compression[89]. They additionally found that Eudragit RS 100 was superior to other grades of Eudragit since little particles with improved drug release profile were got with Eudragit RS 100 [56]. Ketoprofen is a NSAID regularly used for treatment of joint inflammation. The ketoprofen microsponges (ketoprofen and Eudragit RS100) for oral administration were prepared through a QESD method by Baykara and collaborators and investigated the role of process variables such as polymer-drug ratio, stirring speed, polymer-solvent ratio, etc. that affects drug release profile and physical characteristics[90]. Their study results showed that the enhancement in the drug-to-polymer ratio results in decreased microsponges particle size. These researchers additionally inspected the impact of compression pressure for tableting of ketoprofen microsponges by employing a difference in pressure values to mass and report optimal pressure value for tablet compression. The microsponges demonstrated improved compressibility compared to physical mixture of the drug and polymer due to the plastic distortion of sponge-like structure and created precisely solid tablets. They also proved the superiority of ketoprofen microsponges tablets in terms of improved bioavailability to convention ketoprofen tablets. Ketoprofen microsponges
demonstrated effective drug release and absorption that indicates about the tabletting of microsponges. It increases the lag time for drug appearance in plasma and continues the concentration of drug for a longer time period [91]. Nitrendipine belongs to a class of antihypertensive drugs and is poorly water soluble with low oral bioavailability because of elevated first-pass effect. Controlled systems can be beneficial in enhancing the bioavailability of this drug [92]. Cui et al., prepared nitrendipine microsponges by alteration in the QESD method that act like a solid dispersion. The solid dispersion carrier consists of hydroxypropyl methyl cellulose (HPMC), whereas ethyl cellulose and Eudragit RS 100 was used as impeding agent along with anhydrous silicic acid as dispersing agents [93]. Their study suggested that the release rate increases with the increase in the carrier content and dispersing agent. The oral application of nitrendipine microsponges in male dogs showed three times increment in relative bioavailability over ordinary nitrendipine tablets. Kadam et al. developed microsponge-based aceclofenac and discovered that such a system lowers crystallization ability of drug particles along with compacted tablets can be useful for chronic diseases.

7. Recent Advancement in MDDS

MDDS already has a wide range of applications in topical and cosmetic products as well as fewer in oral formulations. But as the time changes, the optimal goal is to bring newer advancement in existing technologies. As a result different advances were made by adjustment of the techniques to shape nanoferrosponges, nanosponges, porous microbeads. As to present scenario nanotechnology rules all scientific regions are porous systems in nanosized and being drawn closer to further progression to correlated micronized. Nanosponges (NS) are further hyper-cross-linked to cyclodextrins (CD) and can be acquired from α-CD, β-CD and γ-CD, either singly or as a blend containing suitable amounts of dextrin, which is structurally linear and cross-linked with a relevant cross-linking agent [94]. The NS exists in solid form and formulated in the form of topical, parenteral, oral, and inhalation dosage [95]. NS offer focusing of dermal delivery to prompting retention on skin and complete reduction in dose and prevent systemic absorption. A limited number of researchers attempted for investigation of nanoporous carriers that entrap dermally suitable elements. Sharma and coworkers developed ethyl cellulose NS as a substitute for econazole nitrate targeting to the skin by incorporating into the hydrogel formulation. Swaminanathan and co-workers developed CD-NS for enhancing itraconazole
solubility. β-cyclodextrin nanosponges were developed for delivery of hydrophilic drugs, in comparison to polymeric microsponges or NS. These NS were developed by cross-linking β-CD moieties by reacting β-CD to diphenyl carbonate. These improved nanosponges were investigated for oral application of DOX hydrochloride, dexamethasone, itraconazole, flurbiprofen, serum albumin, resveratrol, 5-fluorouracil and tamoxifen as exemplary drugs [94,96]. Some researchers incorporated cytotoxic agent in a NS carrier system for enhancing the efficacy of the drugs to target malignant cells [97]. Ferrosponges, i.e., magnetic sponge-like hydrogels were produced by the utilization of an in-situ magnetic nanoparticles (MNPs) synthesis by the use of different concentrations of gelatins [98]. Nanoferrosponge an innovative approach consists of self-working carriers with improved entry to the target site because of the external trigger from magnet and upholds carriers to infiltrate deeper tissue along with afterward expels of magnetic material and leaves porous system. Nanoferrosponges preparation can be done by polymer co-precipitation with magnetite. Ferrosponges exhibit elasticity, swelling ratios in the higher range, hydrophilicity and swift response to an external magnetic trigger for rapid and repeatable swelling-deswelling activities [98]. These have application in a significant number of therapeutic biomolecules and drugs such as NSAIDs, cardiovascular drugs and anticancer agents [99]. Due to the enhanced properties of permeable microspheres, technique was developed to deliver permeable microbeads. These are particles with solid spheres with a diameter range from 5µm-1mm. These are basically synthesized from polypropylene (PP), polyethylene (PE), polyethylene terephthalate (PET), nylon plastics or polymethylmethacrylate (PMMA). They are popularly used in personal care products and cosmetics as exfoliants, in injectable biomaterials as diagnosis in drug delivery as vehicles and in diagnostic devices as diagnostic agents [100].

Passive targeting and active targeting are two major strategies in tumor-targeted drug delivery, which are limited by low permeable vasculature and complex physiological barriers, respectively. For transport cells like stem cells, monocytes/macrophages, and neutrophils, which possess tumor homing capability following cytokine/chemokine gradients, cell-mediated drug delivery can be the most viable strategy to intelligently deliver the drug to the tumor site. Moreover, compared to functionalized exogenous cells as delivery systems, targeting transport cells in peripheral blood can avoid the time-consuming isolation and culture, and further reduce the regulatory hurdles. The most crucial step in achieving this goal is to develop a non-toxic
carrier to be recognized and taken up by transport cells in peripheral blood and achieve triggered
drug release when arriving at the tumor sites. Peptide-based nanosponges are one of the most
promising particles for cell-mediated delivery because of their desirable biocompatibility,
bioimitability, and high drug loading capacity.

8. Stability and Safety Considerations

8.1. Stability Aspects

Pharmaceutically, stability can be stated as the capacity of formulation in particular closure
system or container to restrict any change in its physical, chemical, therapeutic, microbiological
and toxicological specifications [101]. Microsponges can remain stable over a wide biological
pH and, in this way can be utilized as multipurpose carrier systems. They are thermally stable up
to 130°C. Microsponges-based formulations have self-disinfecting properties which limits
bacterial dispersion because of their minute pore size (0.25µm). Microbial passage to the mass is
restricted yet they can develop on micro-sponges surface. International Council on
Harmonization (ICH) guidelines should be followed for performing stability testing of the
microsponges-loaded formulations. Osmani and coworkers developed diclofenac diethylamine-
loaded microsponges and stability evaluation of the gel formulation revealed no change in
appearance, pH, and in vitro drug release behavior. During the stability study, no alteration in
physical appearance and pH was found. The results suggested no critical alteration in
the percentage of drug release and drug content of the formulation. Moreover, a similarity index
of greater than 50 was observed which indicates good stability during 3 months of stability. In
addition, researchers conducted FT-IR of curcumin-loaded microsponges, notwithstanding above
examined parameters. FTIR spectrum reported no indication of drug instability, recommending
the great time span of usability of microsponge delivery system[40,102–106].

8.2. Safety considerations

In other words, the release pattern of the active agent from the MDS was thought to be such a
way that it does not actuate any irritation, genotoxicity, immunogenicity or
cytotoxicity[106,107].

8.2.1. Cytotoxicity studies
Evaluation of the cytotoxicity of microsponge-based drugs is an essential aspect in the improvement of formulation. API and its ingredients may show cytotoxic impact on the microsponges delivery system. The IC\textsubscript{50} and % cell viability values ought to be determined for the drug singly, where drug-loaded microsponges and blank microsponges were evaluated for their cytotoxic activity. Such a similar assessment will portray clarity on cytotoxic effects of readied formulations. Of late, Kumar and coworkers prepared silver sulfadiazine-loaded microsponges gel and evaluated through Draize cytotoxicity test [14]. Silver sulfadiazine is utilized as topical antibacterial agent for burn wounds. \textit{In vitro} cellular toxicity of upgraded gel assessment was done using MTT assay in murine NIH-3T3 Cell line (embryonic fibroblast) and HaCaT Cell line (epidermal keratinocyte) cultures. As per MTT assay, the upgraded gel demonstrated immaterial cytotoxicity, whereas cell feasibility somewhat diminished with increased silver sulfadiazine concentration. The results predicted that silver sulfadiazine did not block cell expansion at 1000 × 10\textsuperscript{-3} mg/ml or even at higher concentrations on both cell lines. Therefore, the upgraded gel demonstrated minimum toxicity on both cell lines which indicated that the prepared formulation had a very less cytotoxicity on dermal cells [102]. Arya and Pathak verified the gastro-retentive capability of microsponges through enhancement of targeted floating curcumin microsponges. The C\textsubscript{max} of plain curcumin and curcumin from microsponges was found to be 0.233 µg/mL and 2.934 µg/mL respectively. An approximately 10-times increase in C\textsubscript{max} value showed enhanced absorption of curcumin, likely because of novel dosage form. A significant increment (4-times) in T\textsubscript{max} was seen in microsponges in comparison with curcumin suggests moderate absorption of curcumin from microsponges and stretched blood circulation [103–105].

9. Conclusions and future perspectives

The number of marketed oral formulations with major limitations such as immediate/burst release and suboptimal drug absorption or rapid clearance from the body. In the novel drug delivery systems, the emergence of micro sponges can uniquely solve problems associated with the conventional oral and topical formulations. Microsponges can capture many hydrophilic and hydrophobic drugs to provide tailored drug release profile in biological medium over the longer period of time. Further, they can absorb the drug 3-fold larger than their own weight. These particular characteristics made them superior over other carrier systems. In addition, this
particular drug delivery not only limited to topicals and oral systems, but also applied to parenteral delivery, colon targeting and pulmonary drug delivery. Furthermore, the microsponges can remain stable at a wider range of pH and temperature up to 130°C. Moreover, their safety parameters also makes them effective for human drug delivery applications.

Microsponges with highly porous cross-linked nanostructured architecture are highly effective to accommodate a variety of drugs with well monitored control drug release characteristics over the extended period of time. On the basis of toxicity studies, various FDA approved polymers such as Eudragit RS100, polymethacrylates polymers, polylactide-co-glycolic acid (PLGA) are used in the development of microsponges. Further, their surface modifications and well transformed behavior into gel structure provides ease of application in the form of creams, gels and lotions. Furthermore, microsponges are used to treat the various disorders like as acne, psoriasis, dandruff, eczema, hair loss and other various dreadful disorders, including cancers. In addition, innovations in technologies led to develop more advanced nano-forms of sponges like as nanoferrosponges, nano-sponges, and porous microbeads which have been documented for variety of drug delivery applications. Further, stability and safety studies on microsponges have confirmed that no significant alteration was observed in the stability without any toxicity.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Consent for Publication

Not applicable.

Funding

None.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.
Acknowledgements

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of education in Saudi Arabia for funding this research work through the project number 20-UQU-IF-P1-001.

References


scale poly (ε-caprolactone) scaffolds using 3D printing and rotational electrospinning for bone tissue regeneration. Addit Manuf. 2020;36(February):101452.


38. Parikh BN, Gothi GD, Patel TD, Chavda H V., Patel CN. Microsponge as novel topical


Available from: https://linkinghub.elsevier.com/retrieve/pii/S037851731000726X


